The protective effect of Guanxinning on panvascular disease in patients with stable angina pectoris

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005556

Enrollment

Unknown

Registered

2022-01-24

Start date

2022-01-24

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable coronary heart disease

Interventions

Control group :Conventional treatment group

Guanxinning Tablet Group :Conventional treatment + Guanxinning tablets

Eligibility

Sex/Gender

All

Age

30 Years to 80 Years

Inclusion criteria

Inclusion criteria: At the same time, it meets the above-mentioned diagnostic criteria for stable coronary heart disease and TCM heart and blood stasis syndrome. Coronary angiography or treadmill exercise test confirms that they are between 30 and 80 years old to participate in this test voluntarily and sign an informed consent form.

Exclusion criteria

Exclusion criteria: ?Patients with unstable angina; ?Combined with acute infection, uncontrolled grade ? hypertension (systolic blood pressure =180mmHg and/or diastolic blood pressure =110mmHg), severe cardiopulmonary insufficiency (heart function grade ?, ?, severe pulmonary insufficiency) , Severe arrhythmia, severe diseases (such as tumors, etc.) and mental illness that affect their survival; ?Recently (6 months) with severe bleeding disease, active bleeding or surgical history; ?Within the past 1 month Patients with acute cerebral infarction and other traumatic brain injuries; ?platelet count <50×10 9 /L, hematocrit 30%; ? abnormal liver and kidney function indexes (ALT and AST exceed the upper limit of the normal reference range by 2 times, Ccr is low Less than 30ml/(min*1.73m2)); ?Patients who are allergic to the test drug (including its ingredients); ?Patients with pregnancy plans or pregnant or lactating women; ?Patients who have participated in other clinical trials within the past 1 month ; ? Alcoholism or drug addicts.

Design outcomes

Primary

Measure	Time frame
Angina Pectoris TCM Syndrome Score;	—

Secondary

Measure	Time frame
Coronary plaque changes;Heart function;Carotid plaque changes;Changes in physical and chemical indicators;Changes in inflammatory factors;	—

Countries

china

Contacts

Public ContactChen Tielong

ctlppp@163.com0571-85827697

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026